Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Name: Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
Published: 2021
License: Public Domain

National Cancer Institute (NCI) · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

advanced fallopian tube carcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic adenocarcinoma, advanced primary peritoneal carcinoma, fallopian tube high grade serous adenocarcinoma, metastatic pancreatic adenocarcinoma, ovarian high grade serous adenocarcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, primary peritoneal high grade serous adenocarcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 839793
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.